These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312 [TBL] [Abstract][Full Text] [Related]
4. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426 [TBL] [Abstract][Full Text] [Related]
5. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Hetzel J; Balletshofer B; Rittig K; Walcher D; Kratzer W; Hombach V; Häring HU; Koenig W; Marx N Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1804-9. PubMed ID: 16002742 [TBL] [Abstract][Full Text] [Related]
6. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639 [TBL] [Abstract][Full Text] [Related]
7. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571 [TBL] [Abstract][Full Text] [Related]
8. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Sidhu JS; Cowan D; Kaski JC Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889 [TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Miyazaki Y; DeFronzo RA Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983 [TBL] [Abstract][Full Text] [Related]
10. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536 [TBL] [Abstract][Full Text] [Related]
11. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484 [TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451 [TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430 [TBL] [Abstract][Full Text] [Related]
14. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744 [TBL] [Abstract][Full Text] [Related]
15. Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients. Lee JK; Chu CH; Chuang MJ; Lin SC; Wang MC; Lu CC; Sun CC; Lam HC Chang Gung Med J; 2006; 29(5):486-92. PubMed ID: 17214393 [TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. van Wijk J; Coll B; Cabezas MC; Koning E; Camps J; Mackness B; Joven J Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1134-7. PubMed ID: 17184491 [TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288 [TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Wang TD; Chen WJ; Lin JW; Chen MF; Lee YT Am J Cardiol; 2004 Feb; 93(3):362-5. PubMed ID: 14759393 [TBL] [Abstract][Full Text] [Related]
19. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Keidar S; Guttmann H; Stam T; Fishman I; Shapira C Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555 [TBL] [Abstract][Full Text] [Related]